Mirjam H M Heemskerk

List of Publications by Year
in descending order

157	7,402	57758	60623
papers	citations	44 h-index	81 g-index

163	163	163	8269
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Identification of Functional HLA-A*01:01â€“Restricted Epstein-Barr Latent Membrane Protein 2â€“Specific T-Cell Receptors. Journal of Infectious Diseases, 2022, 226, 833-842.	4.0	9
2	A broad and systematic approach to identify B cell malignancy-targeting TCRs for multi-antigen-based TÂcell therapy. Molecular Therapy, 2022, 30, 564-578.	8.2	10
3	Comparing CAR and TCR engineered T cell performance as a function of tumor cell exposure. OncoImmunology, 2022, 11, 2033528.	4.6	19
4	Quantitative analysis of mRNA-1273 COVID-19 vaccination response in immunocompromised adult hematology patients. Blood Advances, 2022, 6, 1537-1546.	5.2	45
5	T cell receptor engineering of primary NK cells to therapeutically target tumors and tumor immune evasion. , 2022, 10, e003715.		10
6	Cutting Edge: Unconventional CD8⁺ T Cell Recognition of a Naturally Occurring HLA-A*02:01â€“Restricted 20mer Epitope. Journal of Immunology, 2022, , ji2101208.	0.8	1
7	Prolonged activation of nasal immune cell populations and development of tissue-resident SARS-CoV-2-specific CD8+ T cell responses following COVID-19. Nature Immunology, 2022, 23, 23-32.	14.5	74
8	Ovarian cancer immunogenicity is governed by a narrow subset of progenitor tissue-resident memory TÂcells. Cancer Cell, 2022, 40, 545-557.e13.	16.8	53
9	Chimeric Antigen Receptor (CAR) Regulatory T-Cells in Solid Organ Transplantation. Frontiers in Immunology, 2022, 13, .	4.8	9
10	WT1-specific TCRs directed against newly identified peptides install antitumor reactivity against acute myeloid leukemia and ovarian carcinoma. , 2022, 10, e004409.		9
11	The SPPL3-Defined Glycosphingolipid Repertoire Orchestrates HLA Class I-Mediated Immune Responses. Immunity, 2021, 54, 132-150.e9.	14.3	52
12	Healthy cells functionally present TAP-independent SSR1 peptides: implications for selection of clinically relevant antigens. IScience, 2021, 24, 102051.	4.1	4
13	Clinically applicable CD34+-derived blood dendritic cell subsets exhibit key subset-specific features and potently boost anti-tumor T and NK cell responses. Cancer Immunology, Immunotherapy, 2021, 70, 3167-3181.	4.2	13
14	Targeting human Acyl-CoA:cholesterol acyltransferase as a dual viral and TÂcell metabolic checkpoint. Nature Communications, 2021, 12, 2814.	12.8	54
15	Convalescent Plasma in a Patient with Protracted COVID-19 and Secondary Hypogammaglobulinemia Due to Chronic Lymphocytic Leukemia: Buying Time to Develop Immunity?. Infectious Disease Reports, 2021, 13, 855-864.	3.1	9
16	An HLA-A*11:01-Binding Neoantigen from Mutated NPM1 as Target for TCR Gene Therapy in AML. Cancers, 2021, 13, 5390.	3.7	3
17	Simultaneous Deletion of Endogenous TCRÎ±Î² for TCR Gene Therapy Creates an Improved and Safe Cellular Therapeutic. Molecular Therapy, 2020, 28, 64-74.	8.2	50
18	Peptide Binding to HLA-E Molecules in Humans, Nonhuman Primates, and Mice Reveals Unique Binding Peptides but Remarkably Conserved Anchor Residues. Journal of Immunology, 2020, 205, 2861-2872.	0.8	19

#	Article	IF	Citations
19	HA-1H T-Cell Receptor Gene Transfer to Redirect Virus-Specific T Cells for Treatment of Hematological Malignancies After Allogeneic Stem Cell Transplantation: A Phase 1 Clinical Study. Frontiers in Immunology, 2020, 11, 1804.	4.8	17
20	Immunopeptidome Analysis of HLA-DPB1 Allelic Variants Reveals New Functional Hierarchies. Journal of Immunology, 2020, 204, 3273-3282.	0.8	23
21	Tollâ€like receptor 7/8â€matured RNAâ€transduced dendritic cells as postâ€remission therapy in acute myeloid leukaemia: results of a phase I trial. Clinical and Translational Immunology, 2020, 9, e1117.	3.8	23
22	Framework engineering to produce dominant T cell receptors with enhanced antigen-specific function. Nature Communications, 2019, 10, 4451.	12.8	38
23	Characterization of circulating T-, NK-, and NKT cell subsets in patients with colorectal cancer: the peripheral blood immune cell profile. Cancer Immunology, Immunotherapy, 2019, 68, 1011-1024.	4.2	99
24	Peripheral and systemic antigens elicit an expandable pool of resident memory CD8⁺ T cells in the bone marrow. European Journal of Immunology, 2019, 49, 853-872.	2.9	24
25	Mutated nucleophosmin 1 as immunotherapy target in acute myeloid leukemia. Journal of Clinical Investigation, 2019, 129, 774-785.	8.2	128
26	Abstract A038: Effective rerouting of NK cell cytotoxicity against B-cell malignancies upon TCR gene transfer. , 2019, , .		0
27	Preclinical Strategies to Identify Off-Target Toxicity of High-Affinity TCRs. Molecular Therapy, 2018, 26, 1206-1214.	8.2	33
28	Adoptive Immunotherapy Using PRAME-Specific T Cells in Medulloblastoma. Cancer Research, 2018, 78, 3337-3349.	0.9	64
29	Specific TÂCell Responses against Minor Histocompatibility Antigens Cannot Generally Be Explained by Absence of Their Allelic Counterparts on the Cell Surface. Proteomics, 2018, 18, e1700250.	2.2	34
30	A Jurkat 76 based triple parameter reporter system to evaluate TCR functions and adoptive T cell strategies. Oncotarget, 2018, 9, 17608-17619.	1.8	55
31	PRAME and HLA Class I expression patterns make synovial sarcoma a suitable target for PRAME specific T-cell receptor gene therapy. OncoImmunology, 2018, 7, e1507600.	4.6	28
32	microRNA 125a Regulates MHC-I Expression on Esophageal Adenocarcinoma Cells, Associated With Suppression of Antitumor Immune Response and Poor Outcomes of Patients. Gastroenterology, 2018, 155, 784-798.	1.3	70
33	HLA Class I Antigen Expression in Conjunctival Melanoma Is Not Associated With PD-L1/PD-1 Status. , 2018, 59, 1005.		12
34	Identification of non-mutated neoantigens presented by TAP-deficient tumors. Journal of Experimental Medicine, 2018, 215, 2325-2337.	8.5	64
35	TCR-based therapy for multiple myeloma and other B-cell malignancies targeting intracellular transcription factor BOB1. Blood, 2017, 129, 1284-1295.	1.4	44
36	PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma. JAMA Ophthalmology, 2017, 135, 541.	2.5	87

#	Article	IF	Citations
37	Pulmonary immune responses against Aspergillus fumigatus are characterized by high frequencies of IL-17 producing T-cells. Journal of Infection, 2017, 74, 81-88.	3.3	45
38	Selective graft-versus-leukemia depends on magnitude and diversity of the alloreactive T cell response. Journal of Clinical Investigation, 2017, 127, 517-529.	8.2	107
39	Abstract 3745: Dual-switch TCR: A two-ligand system to control PRAME TCR-modified T cell proliferation and death using inducible MyD88/CD40 and caspase-9. , 2017, , .		0
40	Detection of clinically relevant T-cell receptors requires tailored approaches, and TCR gene therapy carries inherent risks. Translational Cancer Research, 2017, 6, S1118-S1120.	1.0	0
41	Uptake of HLA Alloantigens via CD89 and CD206 Does Not Enhance Antigen Presentation by Indirect Allorecognition. Journal of Immunology Research, 2016, 2016, 1-12.	2.2	1
42	The Epstein-Barr Virus Glycoprotein gp150 Forms an Immune-Evasive Glycan Shield at the Surface of Infected Cells. PLoS Pathogens, 2016, 12, e1005550.	4.7	23
43	746. Go-TCR: Inducible MyD88/CD40 (iMC) Enhances Proliferation and Survival of Tumor-Specific TCR-Modified T Cells, Increasing Anti-Tumor Efficacy. Molecular Therapy, 2016, 24, S294-S295.	8.2	1
44	MB-64ADOPTIVE CELL IMMUNOTHERAPY IN MEDULLOBLASTOMA BASED ON T CELLS REDIRECTED TOWARD TUMOR CELLS BY PRAME SPECIFIC Î±Î²TCR GENE MODIFICATION. Neuro-Oncology, 2016, 18, iii111.3-iii111.	1.2	0
45	CLEC12A-Mediated Antigen Uptake and Cross-Presentation by Human Dendritic Cell Subsets Efficiently Boost Tumor-Reactive T Cell Responses. Journal of Immunology, 2016, 197, 2715-2725.	0.8	43
46	Inducible MyD88/CD40 (iMC) Enhances Proliferation and Survival of Tumor-Specific TCR-Modified T Cells and Improves Anti-Tumor Efficacy in Myeloma. Blood, 2016, 128, 4550-4550.	1.4	2
47	Induction of Antigen-Specific T-Cell Responses through Dendritic Cell Vaccination in AML: Results of a Phase I/II Trial and Ex Vivo Enhancement By Checkpoint Blockade. Blood, 2016, 128, 764-764.	1.4	10
48	Endogenous Immunoglobulin-Derived Neoepitopes Are Processed and Form a Sizeable Fraction of the HLA Class I Ligandome of Human Lymphoma Cells. Blood, 2016, 128, 914-914.	1.4	1
49	A CD22-reactive TCR from the T-cell allorepertoire for the treatment of acute lymphoblastic leukemia by TCR gene transfer. Oncotarget, 2016, 7, 71536-71547.	1.8	7
50	Generation of CD20-specific TCRs for TCR gene therapy of CD20low B-cell malignancies insusceptible to CD20-targeting antibodies. Oncotarget, 2016, 7, 77021-77037.	1.8	24
51	Abstract LB-084: Go-TCRâ„¢: Inducible MyD88/CD40 (iMC) enhances proliferation and survival of tumor-specific TCR-modified T cells, increasing anti-tumor efficacy. , 2016, , .		0
52	Abstract B078: GoTCR: Inducible MyD88/CD40 (iMC) enhances proliferation and survival of tumor-specific TCR-modified T cells and improves antitumor efficacy in myeloma. , 2016, , .		0
53	Abstract B002: TLR7/8-matured dendritic cells for therapeutic vaccination in AML: Results of a clinical Phase I/II trial. , 2016, , .		0
54	Therapeutic targeting of the BCR-associated protein CD79b in a TCR-based approach is hampered by aberrant expression of CD79b. Blood, 2015, 125, 949-958.	1.4	17

#	Article	IF	Citations
55	The molecular bases of ÎĨ² T-cell mediated antigen recognition. Acta Crystallographica Section A: Foundations and Advances, 2015, 71, s238-s238.	0.1	0
56	Design and validation of conditional ligands for <scp>HLAâ€Ɓ</scp>*08:01, <scp>HLAâ€Ɓ</scp>*15:01, <scp>HLAâ€Ɓ</scp>*35:01, and <scp>HLAâ€Ɓ</scp>*44:05. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2015, 87, 967-975.	1.5	21
57	Identification of Biological Relevant Minor Histocompatibility Antigens within the B-lymphocyteâ€"Derived HLA-Ligandome Using a Reverse Immunology Approach. Clinical Cancer Research, 2015, 21, 2177-2186.	7.0	36
58	Naturally Processed Non-canonical HLA-A*02:01 Presented Peptides. Journal of Biological Chemistry, 2015, 290, 2593-2603.	3.4	89
59	Cytomegalovirus-Induced Expression of CD244 after Liver Transplantation Is Associated with CD8+ T Cell Hyporesponsiveness to Alloantigen. Journal of Immunology, 2015, 195, 1838-1848.	0.8	13
60	Inducible MyD88/CD40 Enhances Proliferation and Survival of PRAME-Specific TCR-Engineered T Cells and Increases Anti-Tumor Effects in Myeloma. Blood, 2015, 126, 1886-1886.	1.4	1
61	T Cell Receptor Gene Therapy Targeting the Intracellular Transcription Factor Bob1 for the Treatment of Multiple Myeloma and Other B Cell Malignancies. Blood, 2015, 126, 3002-3002.	1.4	1
62	Natural killer cells facilitate PRAME-specific T-cell reactivity against neuroblastoma. Oncotarget, 2015, 6, 35770-35781.	1.8	37
63	The molecular bases of Î´/Î±Î² T cellâ€"mediated antigen recognition. Journal of Experimental Medicine, 2014, 211, 2599-2615.	8.5	52
64	HLA Monomers as a Tool to Monitor Indirect Allorecognition. Transplantation, 2014, 97, 1119-1127.	1.0	12
65	Accurate quantitation of MHC-bound peptides by application of isotopically labeled peptide MHC complexes. Journal of Proteomics, 2014, 109, 240-244.	2.4	63
66	Early Cytomegalovirus Reactivation Leaves a Specific and Dynamic Imprint on the Reconstituting T Cell Compartment Long-Term after Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2014, 20, 655-661.	2.0	50
67	Induction of A. fumigatus-specific CD4-positive T cells in patients recovering from invasive aspergillosis. Haematologica, 2014, 99, 1255-1263.	3.5	31
68	A Good Manufacturing Practice procedure to engineer donor virus-specific T cells into potent anti-leukemic effector cells. Haematologica, 2014, 99, 759-768.	3.5	37
69	T Cell Receptors Specific for the Intracellular Transcription Factor Bob1 Allow Efficient Targeting of Human B Cell Leukemia and Multiple Myeloma. Blood, 2014, 124, 3832-3832.	1.4	1
70	Functional Evaluation of T-Cells Generated from WT1-TCR Transduced Human Hematopoietic Stem Cells Using the OP9-DL1 Coculture System. Blood, 2014, 124, 2152-2152.	1.4	0
71	High-Affinity CD20-Specific T-Cell Receptors Suitable for Adoptive Immunotherapy in the Treatment of CD20low B-Cell Malignancies. Blood, 2014, 124, 3837-3837.	1.4	0
72	High-throughput identification of antigen-specific TCRs by TCR gene capture. Nature Medicine, 2013, 19, 1534-1541.	30.7	166

#	Article	IF	Citations
73	The Human Leukocyte Antigenâ€“presented Ligandome of B Lymphocytes. Molecular and Cellular Proteomics, 2013, 12, 1829-1843.	3.8	113
74	Characterization of the T-Cellâ€“Mediated Immune Response Against the Aspergillus fumigatus Proteins Crf1 and Catalase 1 in Healthy Individuals. Journal of Infectious Diseases, 2013, 208, 847-856.	4.0	37
75	Mixed functional characteristics correlating with <scp>TCR</scp>â€ligand k_{off}â€rate of <scp>MHC</scp>â€tetramer reactive <scp>T</scp> cells within the naive <scp>T</scp>â€cell repertoire. European Journal of Immunology, 2013, 43, 3038-3050.	2.9	27
76	Multi-cistronic vector encoding optimized safety switch for adoptive therapy with T-cell receptor-modified T cells. Gene Therapy, 2013, 20, 861-867.	4.5	11
77	Discovery of T Cell Epitopes Implementing HLA-Peptidomics into a Reverse Immunology Approach. Journal of Immunology, 2013, 190, 3869-3877.	0.8	40
78	Extracellular Domains of CD8Î± and CD8ÃŸ Subunits Are Sufficient for HLA Class I Restricted Helper Functions of TCR-Engineered CD4+ T Cells. PLoS ONE, 2013, 8, e65212.	2.5	15
79	Imprint Of Early CMV Reactivation On The Reconstituting T-Lymphocyte Compartment One and Two Year After Hematopoietic Stem Cell Transplantation. Blood, 2013, 122, 3295-3295.	1.4	0
80	TCR-transgenic lymphocytes specific for HMMR/Rhamm limit tumor outgrowth in vivo. Blood, 2012, 119, 3440-3449.	1.4	55
81	Identification of a Coordinated CD8 and CD4 T Cell Response Directed Against Mismatched HLA Class I Causing Severe Acute Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2012, 18, 210-219.	2.0	26
82	High-Throughput Identification of Potential Minor Histocompatibility Antigens by MHC Tetramer-Based Screening: Feasibility and Limitations. PLoS ONE, 2011, 6, e22523.	2.5	36
83	Rapid Re-expression of Retrovirally Introduced VersusEndogenous TCRs in Engineered T cells AfterAntigen-specific Stimulation. Journal of Immunotherapy, 2011, 34, 165-174.	2.4	11
84	Optimization of the HA-1-specific T-cell receptor for gene therapy of hematologic malignancies. Haematologica, 2011, 96, 477-481.	3.5	36
85	Allo-HLAâ€“reactive T cells inducing graft-versus-host disease are single peptide specific. Blood, 2011, 118, 6733-6742.	1.4	64
86	Generating HPV specific T helper cells for the treatment of HPV induced malignancies using TCR gene transfer. Journal of Translational Medicine, 2011, 9, 147.	4.4	27
87	PRAME-Specific Allo-HLAâ€“Restricted T Cells with Potent Antitumor Reactivity Useful for Therapeutic T-Cell Receptor Gene Transfer. Clinical Cancer Research, 2011, 17, 5615-5625.	7.0	104
88	Allogeneic HLA-A*02â€“Restricted WT1-Specific T Cells from Mismatched Donors Are Highly Reactive but Show Off-Target Promiscuity. Journal of Immunology, 2011, 187, 2824-2833.	0.8	37
89	Occurrence of T Cells Specific for the Aspergillus Proteins Crf1 and Catalase1 in Patients Recovering From Invasive Aspergillosis. Blood, 2011, 118, 3008-3008.	1.4	0
90	HLA-Peptidomics and the Identification of Clinical Relevant Minor Histocompatibility Antigens,. Blood, 2011, 118, 4038-4038.	1.4	0

#	Article	IF	Citations
91	T-cell receptor gene transfer for the treatment of leukemia and other tumors. Haematologica, 2010, 95, 15-19.	3.5	15
92	Allo-HLA reactivity of virus-specific memory T cells is common. Blood, 2010, 115, 3146-3157.	1.4	270
93	Mixed T cell receptor dimers harbor potentially harmful neoreactivity. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 10972-10977.	7.1	196
94	Transduction of Human T Cells with a Novel T-Cell Receptor Confers Anti-HCV Reactivity. PLoS Pathogens, 2010, 6, e1001018.	4.7	46
95	Identification of Multiple HLA Class II Epitopes of Aspergillus Fumigatus by Generation of CD4+ T Cell Clones Recognizing the A. Fumigatus proteins Crf1 and Catalase1. Blood, 2010, 116, 2332-2332.	1.4	2
96	Kinetic Preservation of Dual Specificity of Coprogrammed Minor Histocompatibility Antigen-Reactive Virus-Specific T Cells. Cancer Research, 2009, 69, 2034-2041.	0.9	21
97	Î±Î² T Cell Receptor Transfer to Î³Î´ T Cells Generates Functional Effector Cells without Mixed TCR Dimers In Vivo. Journal of Immunology, 2009, 182, 164-170.	0.8	57
98	Identification of Varicella-Zoster Virus-Specific CD8 T Cells in Patients after T-Cell-Depleted Allogeneic Stem Cell Transplantation. Journal of Virology, 2009, 83, 7361-7364.	3.4	16
99	Functional Analysis of Killer Ig-Like Receptor-Expressing Cytomegalovirus-Specific CD8+ T Cells. Journal of Immunology, 2009, 182, 92-101.	0.8	46
100	Parallel detection of antigen-specific T-cell responses by multidimensional encoding of MHC multimers. Nature Methods, 2009, 6, 520-526.	19.0	286
101	New tools to monitor the impact of viral infection on the alloreactive Tâ€cell repertoire. Tissue Antigens, 2009, 74, 290-297.	1.0	32
102	Retroviral transfer of human CD20 as a suicide gene for adoptive T-cell therapy. Haematologica, 2009, 94, 1316-1320.	3.5	121
103	Allogeneic disparities in immunoglobulin-like transcript 5 induce potent antibody responses in hematopoietic stem cell transplant recipients. Blood, 2009, 114, 2323-2332.	1.4	29
104	High Avidity PRAME Specific T Cells Derived From In Vivo HLA Mismatched Transplantation Setting Potentially Useful for Immunotherapeutic Strategies.. Blood, 2009, 114, 4087-4087.	1.4	1
105	Allogeneic HLA-A2-Restricted WT1-Specific T Cells From Mismatched Donors Are Highly Reactive but Show Potentially Hazardous Promiscuity.. Blood, 2009, 114, 4081-4081.	1.4	5
106	Optimization of the HA-1-Specific T Cell Receptor for Gene Therapy of Hematological Malignancies.. Blood, 2009, 114, 4093-4093.	1.4	0
107	Extracellular Domains of CD8a and Î² Subunits Are Required and Sufficient for HLA Class I Restricted Helper Activity of TCR-Engineered CD4+ T Cells.. Blood, 2009, 114, 3574-3574.	1.4	0
108	Generation of CMV Specific T Cells From CMV Seronegative Donors by T Cell Receptor RNA Transfer.. Blood, 2009, 114, 3577-3577.	1.4	0

#	Article	IF	Citations
109	Monitoring of indirect allorecognition: wishful thinking or solid data?. Tissue Antigens, 2008, 71, 1-15.	1.0	19
110	HLA-DP as specific target for cellular immunotherapy in HLA class II-expressing B-cell leukemia. Leukemia, 2008, 22, 1387-1394.	7.2	60
111	Transcriptional silencing of RFXAP in MHC class II-deficiencyâˆ†. Molecular Immunology, 2008, 45, 2920-2928.	2.2	10
112	T-cell receptor gene transfer for treatment of leukemia. Cytotherapy, 2008, 10, 108-115.	0.7	11
113	Conditional MHC class I ligands and peptide exchange technology for the human MHC gene products HLA-A1, -A3, -A11, and -B7. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 3825-3830.	7.1	150
114	Varicellovirus UL49.5 Proteins Differentially Affect the Function of the Transporter Associated with Antigen Processing, TAP. PLoS Pathogens, 2008, 4, e1000080.	4.7	68
115	Defective synthesis or association of T-cell receptor chains underlies loss of surface T-cell receptorâ€“CD3 expression in enteropathy-associated T-cell lymphoma. Blood, 2008, 112, 5103-5110.	1.4	45
116	Genetic engineering of virus-specific T cells with T-cell receptors recognizing minor histocompatibility antigens for clinical application. Haematologica, 2008, 93, 1535-1543.	3.5	38
117	Alloreactivity of Virus Specific T-Cells.. Blood, 2008, 112, 3249-3249.	1.4	0
118	Recombination of Endogenous TCR Chains with Retrovirally Introduced TCR Chains Can Result in Mixed T Cell Receptor Dimers Harbouring Harmful Alloreactivity. Blood, 2008, 112, 823-823.	1.4	0
119	Leukemic Blasts Acting as Host Antigen Presenting Cells Trigger a Combined CD4 and CD8 Allo-Immune Response Directed against Mismatched HLA Class I. Blood, 2008, 112, 4607-4607.	1.4	0
120	SNP-Based Genome-Wide Identification of Hematopoiesis-Restricted Minor Histocompatibility Antigens. Blood, 2008, 112, 814-814.	1.4	5
121	Functional Human Antigen-Specific T Cells Produced In Vitro Using Retroviral T Cell Receptor Transfer into Hematopoietic Progenitors. Journal of Immunology, 2007, 179, 4959-4968.	0.8	44
122	Efficiency of T-cell receptor expression in dual-specific T cells is controlled by the intrinsic qualities of the TCR chains within the TCR-CD3 complex. Blood, 2007, 109, 235-243.	1.4	156
123	Multiple myelomaâ€“reactive T cells recognize an activation-induced minor histocompatibility antigen encoded by the ATP-dependent interferon-responsive (ADIR) gene. Blood, 2007, 109, 4089-4096.	1.4	90
124	Differential activation of the death receptor pathway in human target cells induced by cytotoxic T lymphocytes showing different kinetics of killing. Haematologica, 2007, 92, 1671-1678.	3.5	14
125	Involvement of caspase-8 in chemotherapy-induced apoptosis of patient derived leukemia cell lines independent of the death receptor pathway and downstream from mitochondria. Apoptosis: an International Journal on Programmed Cell Death, 2007, 12, 181-193.	4.9	18
126	Optimizing TCR gene transfer. Clinical Immunology, 2006, 119, 121-122.	3.2	4

#	Article	IF	Citations
127	Pretransplantation CMV-specific T cells protect recipients of T-cell-depleted grafts against CMV-related complications. Blood, 2006, 107, 389-396.	1.4	59
128	Strong selection of virus-specific cytotoxic CD4+ T-cell clones during primary human cytomegalovirus infection. Blood, 2006, 108, 3121-3127.	1.4	93
129	Molecular persistence of chronic myeloid leukemia caused by donor T cells specific for lineage-restricted maturation antigens not recognizing immature progenitor-cells. Leukemia, 2006, 20, 1040-1046.	7.2	16
130	Rapid assessment of the antigenic integrity of tetrameric HLA complexes by human monoclonal HLA antibodies. Journal of Immunological Methods, 2006, 315, 153-161.	1.4	9
131	Designer T cells by T cell receptor replacement. European Journal of Immunology, 2006, 36, 3052-3059.	2.9	89
132	Î±Î² T-Cell Receptor Engineered Î³Î´ T Cells Mediate Effective Antileukemic Reactivity. Cancer Research, 2006, 66, 3331-3337.	0.9	92
133	GVHD in HLA-A2 Mismatched Transplantation Caused by a Combined CD8 Response Directed Against HLA-A2 and a CD4 Response Recognizing an HLA-A2 Derived Peptide in HLA-DR1.. Blood, 2006, 108, 5164-5164.	1.4	0
134	ATP Dependent Interferon Responsive (ADIR) Gene Encodes an Activation Induced Minor Histocompatibility Antigen Recognized on Multiple Myeloma by CD8+ T Cells.. Blood, 2006, 108, 549-549.	1.4	0
135	HLA class II restricted T-cell receptor gene transfer generates CD4+ T cells with helper activity as well as cytotoxic capacity. Gene Therapy, 2005, 12, 1686-1695.	4.5	24
136	Impact of Peptides on the Recognition of HLA Class I Molecules by Human HLA Antibodies. Journal of Immunology, 2005, 175, 5950-5957.	0.8	46
137	Retroviral Gene Transfer of T Cell Receptors (TCR) Specific for Minor Histocompatibility Antigens to Virus-Specific T Cells as Cellular Immunotherapy of Patients with Relapsed Hematological Malignancies after Allogeneic Stem Cell Transplantation.. Blood, 2005, 106, 5529-5529.	1.4	0
138	Re-Engineering Î³ Î´ T Cells by Î± Î² T Cell Receptor Gene Transfer Creates Potent Effector Cells with Anti-Leukemic Reactivity.. Blood, 2005, 106, 1288-1288.	1.4	0
139	Physiological TCR Modulation after Antigen Specific Triggering of Introduced TCRs under Control of a Retroviral Promotor.. Blood, 2005, 106, 5537-5537.	1.4	0
140	Adult and cord blood T cells can acquire HA-1 specificity through HA-1 T-cell receptor gene transfer. Haematologica, 2005, 90, 1415-21.	3.5	31
141	Reprogramming of Virus-specific T Cells into Leukemia-reactive T Cells Using T Cell Receptor Gene Transfer. Journal of Experimental Medicine, 2004, 199, 885-894.	8.5	176
142	The Functional Activity of Genetically Engineered T Cell Receptor Transferred T Cells Is Highly Dependent on Pairing Properties of the Transferred TCR Î± and Î² Chains.. Blood, 2004, 104, 1753-1753.	1.4	1
143	Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 2742-2747.	7.1	400
144	Redirection of antileukemic reactivity of peripheral T lymphocytes using gene transfer of minor histocompatibility antigen HA-2-specific T-cell receptor complexes expressing a conserved alpha joining region. Blood, 2003, 102, 3530-3540.	1.4	204

#	Article	IF	Citations
145	Functional role of alternatively spliced deoxycytidine kinase in sensitivity to cytarabine of acute myeloid leukemic cells. Blood, 2002, 99, 1373-1380.	1.4	46
146	Minor histocompatibility antigens as targets of graft-versus-leukemia reactions. Current Opinion in Hematology, 2002, 9, 497-502.	2.5	46
147	Mesenchymal stem cells promote engraftment of human umbilical cord bloodâ€“derived CD34+ cells in NOD/SCID mice. Experimental Hematology, 2002, 30, 870-878.	0.4	470
148	Dual HLA class I and class II restricted recognition of alloreactive T lymphocytes mediated by a single T cell receptor complex. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 6806-6811.	7.1	79
149	TCR Gene Rearrangements and Expression of the Pre-T Cell Receptor Complex During Human T-Cell Differentiation. Blood, 1999, 93, 3033-3043.	1.4	116
150	Genetic Modification of Human B-Cell Development: B-Cell Development Is Inhibited by the Dominant Negative Helix Loop Helix Factor Id3. Blood, 1999, 94, 2637-2646.	1.4	69
151	Enrichment of an Antigen-Specific T Cell Response by Retrovirally Transduced Human Dendritic Cells. Cellular Immunology, 1999, 195, 10-17.	3.0	67
152	Disruption of Î±Î² but not of Î³Î´ T cell development by overexpression of the helixâ€“loopâ€“helix protein Id3 in committed T cell progenitors. EMBO Journal, 1999, 18, 2793-2802.	7.8	91
153	TCR Gene Rearrangements and Expression of the Pre-T Cell Receptor Complex During Human T-Cell Differentiation. Blood, 1999, 93, 3033-3043.	1.4	44
154	Early stages in the development of human T, natural killer and thymic dendritic cells. Immunological Reviews, 1998, 165, 75-86.	6.0	168
155	Inhibition of T Cell and Promotion of Natural Killer Cell Development by the Dominant Negative Helix Loop Helix Factor Id3. Journal of Experimental Medicine, 1997, 186, 1597-1602.	8.5	255
156	Activation of virus-specific major histocompatibility complex class II-restricted CD8+ cytotoxic T cells in CD4-deficient mice. European Journal of Immunology, 1995, 25, 1109-1112.	2.9	15
157	Determination of the Cytotoxic T Cell Epitopes of Mouse Hepatitis Virus, Using Elution of Viral Peptides from Class I MHC Molecules as an Approach. Advances in Experimental Medicine and Biology, 1994, 342, 407-412.	1.6	1